2-amino-1-(4-hydroxybenzyl)imidazole | 123593-06-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-amino-1-(4-hydroxybenzyl)imidazole
• 英文别名: 4-[(2-amino-1H-imidazol-1-yl)methyl]-Phenol；4-[(2-aminoimidazol-1-yl)methyl]phenol
• CAS: 123593-06-6
• 化学式: C₁₀H₁₁N₃O
• 分子量: 189.217
• InChiKey: LUIPDSMHTCPAAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  64.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-amino-1-(4-methoxybenzyl)imidazole hydrochloride 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 2-amino-1-(4-hydroxybenzyl)imidazole
  参考文献：
  名称：

  Some benzyl-substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine .beta.-hydroxylase. 4. Structure-activity relationships at the copper binding site

  摘要：

  Structure-activity relationships (SAR) were determined for novel multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1) by examining the effects upon in vitro inhibitory potencies resulting from structural changes at the copper-binding region of inhibitor. Attempts were made to determine replacement groups for the thione sulfur atom of the prototypical inhibitor 1-(4-hydroxybenzyl)imidazole-2-thione described previously. The synthesis and evaluation of oxygen and nitrogen analogues of the soft thione group demonstrated the sulfur atom to be necessary for optimal activity. An additional series of imidazole-2-thione relatives was prepared in an effort to probe the relationship between the pKa of the ligand group and inhibitory potency. In vitro inhibitory potency was shown not to correlate with ligand pKa over a range of approximately 10 pKa units, and a rationale for this is advanced. Additional ligand modifications were prepared in order to explore bulk tolerance at the enzyme oxygen binding site and to determine the effects of substituting a six-membered ligand group for the five-membered imidazole-2-thione ligand.

  DOI：

  10.1021/jm00164a051

文献信息

• Propanoic acid derivatives
  申请人：Celltech Therapeutics Limited

  公开号：US20020035092A1

  公开（公告）日：2002-03-21

  Propanoic acid derivatives of formula (1) are described: Ar—X 1 —Ar 1 —Z—R  (1) in which Ar is a nitrogen base containing group; X 1 is linker atom or group; Ar 1 is an optionally substituted 5- or 6-membered nitrogen-containing aromatic or non-aromatic monocycle; Z is a group —CH(R 13 )CH 2 — [in which R 13 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group], —C(R 12a )(R 13 )—CH(R 12b )— [in which R 12a and R 12b together with the carbon atoms to which they are attached form a C 3-7 cycloalkyl group] or C(R 13 )═CH—; R is a carboxylic acid (—CO 2 H) or a derivative or biostere thereof; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of &agr; v integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders.

  描述了化学式（1）的丙酸衍生物： Ar-X1-Ar1-Z-R  (1) 其中，Ar是含氮基团；X1是连接原子或基团；Ar1是可选地取代的含氮芳香或非芳香单环的5-或6-成员；Z是一个基团-CH（R13）CH2- [其中R13是可选的脂肪，环状脂肪，杂原子脂肪，杂环状脂肪，芳香或杂芳香基团]，-C（R12a）（R13）-CH（R12b）- [其中R12a和R12b与它们所连接的碳原子共同形成C3-7环烷基团]或C（R13）HCH- ；R是羧酸（-CO2H）或其衍生物或生物立体异构体；以及它们的盐，溶剂合物，水合物和N-氧化物。这些化合物能够抑制αv整合素与其配体的结合，并可用于预防和治疗免疫或炎症性疾病。
• US6319922B1
  申请人：——

  公开号：US6319922B1

  公开（公告）日：2001-11-20